Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD
Published: Thursday, Dec 07, 2017



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.

Clinicians are still not sure how to best implement pertuzumab into the disease course, says Brufsky. The question is, he says, is extra pertuzumab necessary?

Brufsky says that a lot of clinicians will give upfront neoadjuvant therapy with pertuzumab, and then have to decide about additional doses.
 


Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.

Clinicians are still not sure how to best implement pertuzumab into the disease course, says Brufsky. The question is, he says, is extra pertuzumab necessary?

Brufsky says that a lot of clinicians will give upfront neoadjuvant therapy with pertuzumab, and then have to decide about additional doses.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x